トリロスタン
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 “Trilostane in advanced breast cancer”. Expert Opin Pharmacother 7 (17): 2413–9. (December 2006). doi:10.1517/14656566.7.17.2413. PMID 17109615.
1 2 J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1245–. ISBN 978-1-4757-2085-3. https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA1245
1 2 I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 281–. ISBN 978-94-011-4439-1. https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA281
↑ Martin Negwer (1987).
1 2 “Treating Cushing's Disease in Dogs”. US Food and Drug Administration. 2011年4月3日閲覧。
1 2 3 “Vetoryl-Contraindications”. NOAH Compendium of Animal Health-National Office of Animal Health UK. 2011年4月3日閲覧。
1 2 “Dechra US Datasheet-Vetoryl”. Dechra US. 2011年4月3日閲覧。 (PDF)
↑ “Cushing's Disease in Dogs” (英語). NASC LIVE. 2021年1月4日閲覧。
↑ de Gier J; Wolthers CH; Galac S; Okkens AC; Kooistra HS (April 2011). “Effects of the 3β-hydroxysteroid dehydrogenase inhibitor trilostane on luteal progesterone production in the dog”. Theriogenology 75 (7): 1271–9. doi:10.1016/j.theriogenology.2010.11.041. PMID 21295836.
↑ Reusch, Claudia E. (2006年). “Trilostane-5 Years of Clinical Experience for the Treatment of Cushing's Disease”.